RESUMO
Objective:To retrospectively analyze clinical efficacy and safety of omalizumab in the treatment of chronic urticaria (CU) in southern Zhejiang, China.Methods:A retrospective observational study was conducted on CU patients who received omalizumab treatment at the First Affiliated Hospital of Wenzhou Medical University from January 1st, 2018 to August 1st, 2021. Through the outpatient follow-up visits, the disease activity, condition control, and quality of life were evaluated using the 7-day urticaria activity score (UAS7) , urticaria control test (UCT) , and dermatology life quality index (DLQI) . In addition, changes in disease condition, recurrence after withdrawal, and adverse events were assessed. Independent-sample t test was used for intergroup comparisons of normally distributed measurement data, Wilcoxon signed-rank sum test or Kruskal-Wallis H test was used for comparisons of non-normally distributed measurement data, and chi-square test or Fisher′s exact test was used for comparisons of enumeration data. Results:A total of 252 CU patients with poor response to antihistamines were included, with a baseline UCT score of 5.0 ± 2.4 points, a UAS7 score of 25.6 ± 6.2 points, and a DLQI score of 17.5 ± 4.7 points; among them, 204 (81.0%) were treated with omalizumab at an initial dose of 300 mg, and 48 (19.0%) with omalizumab at an initial dose of 150 mg. At the end points (12.0 ± 1.4 months after the start of treatment) , an overall control rate of 90.3% (224/248) was achieved after the omalizumab treatment; concretely, 137 (55.2%) patients achieved complete control (UCT = 16 points) , 87 (35.1%) achieved partial control (12 points ≤ UCT < 16 points) , and 24 (9.7%) showed no response (UCT < 12 points) , while 10 with partial response shifted to complete control after dose increase. During the treatment period, recurrence occurred in 50 patients (36.5%) , of whom 32 patients opted for retreatment with omalizumab, and then 30 (93.8%) achieved partial or complete control. Adverse events were reported in 8 patients (3.2%) , and all were mild or moderate.Conclusion:Omalizumab was effective in the real-world treatment of CU, and could improve patients′ quality of life, with a favorable safety profile.
RESUMO
Objective To investigate the changes of lithium metabolic balance in normal controls and in patients with type-two diabetes mellitus.Method Lithium was measured by atomic absorbent spectrometry.Results (2 91?0 54)?mol/d of lithium intake (2 37?0 51)?mol/d in urine and (0 28?0 05)?mol/d in stool,(0 27?0 24)?mol/d of lithium equilibrium value(LEV),(2 64?0 51)?mol/d of intestinal lithium absorption value(ILAV),(90 4?18)% of intestinal lithium absorption rate(ILAR) and (81 0?1 5)% of ratio of urine lithium excretion to lithium intake(ULE/LI)in normal controls;as well as (2 24?0 25)?mol/d of lithium in food,(2 15?0 36)?mol/d in urine,(0 35?0 05)?mol/d in stool,(-0 25?0 06)?mol/d of LEV,(1 89?0 33)?mol/d of ILAV,(84 3?2 1)% of ILAR and (95 6?3 2)% RU/I in diabetic patients respectively.Lithium in food and stool,LEV,ILAV and ILAR in diabetes were lower than those in controls (P
RESUMO
Objective To investigate the status of apoptosis of osteoblast, osteoclast and the relative factors. Methods Apoptotic cells were examined using in situ end labeling technique. Expressions of bcl-2, Fas and transforming growth factor(TGF)β1 were observed with immunohistochemical method. Results Positive expression rate (40.5±5.2)% of apoptosis cells was significantly increased in the osteoblast, but the expression rate of apoptosis cells (8.4±1.2)% was significantly decreased in the osteoclast of the post-ovariectomy rats than in the sham-operated rats. The expression of Fas was decreased in osteoclast (20.0%) and increased in osteoblast (80.0%) of the post-ovariectomized rats. The expression of TGFβ1 was significantly decreased in the osteoclast (0) and the osteoblast (20.0%) of the post-ovariectomized rats. The above-mentioned targets in post-ovariectomized rats treated with nilestriol/levonorgestrel were close to those sham-operated rats (P＞0.05). Conclusions Bone loss in the post-ovariectomized rats is attributable to the lower level of estrogen so that the apoptosis cells were decreased in osteoclast but were increased in osteoblast. As a result, the process of bone absorption prevails over that of bone formation. Expression of TGFβ1 depends on stimulation of estrogen. TGFβ1 may stimulate apoptosis of osteoclast and restrain apoptosis of osteoblast. Fas can induce the apoptosis of osteoclast.
RESUMO
Dual-energy X-ray absorptiometry(DEXA),scanning electron microscopy,and bone biomechanical test were used to assess comprehensively bone quantity and quality of ovariectomized rats. In OVX rats,not only bone mineral density (BMD) of lumbar vertebrae in vivo and vitro,but also BMD of femora (except for R3 region) and proximal metaphysis(R1 region) in vitro decreased obviously (P<0.01)，whose bone loss rates of L5 and L6 were the highest and achieved 13%; the trabeculae of OVX rats were few，fine, and discontinued and there were lacunae on the surface;in OVX rats,both compressive strength of vertebral bodies and the mechanical properties of femora decreased;the falling degree of the former was greater;the maximal compressive power of lumbar vertebrae decreased with 33.32%. We conclude that after 4-month post-ovariectomy, the bone quantity and quality of six-month-old rats decreased, especially in the area of abundant cancellous bone such as vertebral bodies,distal femora; the assessment of the efficiency of new drugs to prevent and treat postmenopausal osteoporosis using rat models should include these drugs' effects to the bone mass, the bone structure, and the bone strength.
RESUMO
The effects of glipizide on SI、SG、KG、Iarea 0～20min、FBG、FINS with minimal model in non-insulin-dependent diabetes meIlitus were observed.The results showed SI、SG、KG、Iarea 0～20min were lower and FBG was higher in NIDDM than these in normal subjects before glipizide therapy.After two weeks of glipizide therapy,FBG was decreased and SI、SG、KG、Iarea 0～20min were increased.These data suggested that glipizide not only had the effect on stimulating islet ?-cell secretion,but also improving insulin sensitivity and glucose effectiveness.
RESUMO
With the increasing of human mean life span,the prevalence of primary osteoporosis is also raised.The knowledge about the prevention and the therapy of primary osteoporosis should be well grasped for our endocrinologists.
RESUMO
The diagnostic value of glutamic acid decarboxylase antibody (GAD 65-Ab) was more valuable than islet cell antibody (ICA) in type 1 diabetes mellitus by receiver-operating characteristic (ROC) curves; likelihood ratios of different regions of GAD 65-Ab and ICA could reflect the probability of type 1 diabetes mellitus.
RESUMO
Objective To study the characteristics of ? cell function change and to explore the predictive value of glutamic acid decarboxylase (GAD)-Ab and other factors for ? cell function in the patients with latent autoimmune diabetes of adults (LADA). Methods Sixteen LADA patients (positive GAD-Ab) and 24 type 2 diabetic patients (negative GAD-Ab) were followed-up at 0, 6th, 12th, 30th, 36th, 42th and 48th months respectively. Their fasting and postprandial 2h C-peptide and glycemic control were measured. GAD-Ab was determined by radioimmunoprecipitation assay and C-peptide by RIA. Results Decreased fasting C peptide (FCP) levels (Month 30, 36, 42, 48 compared with Month 0, P
RESUMO
Determinations of urinary ionic calcium with selective calcium ionic electrode and urinary total calcium by means of standard addition method were performed on 15 patients with hypoparathyroidism. The urinary ionic calcium level was 18.45 ? 10.75 mg/24 hr, which was significantly below normal (P
RESUMO
Zinc(Zn) and copper(Cu) balance tests were conducted in patients with diabetes mellitus. The results revealed that the negative balance of Zn and excessive positive balance of Cu were much improved after the management of diabetes mellitus. In addition, a close relationship was found between serum glucose concentration and the disorder of Zn and Cu balance, i.e. serum Zn level, apparent intestinal absorption rate and balance status of Zn were reversely related to serum glucose concentration, whereas urinary Zn, serum Cu level and apparent intestinal absorption of Cu were positively correlated to serum glucose concentration. Poly-factor analysis suggested that hyperzincuria and malabsorption of Zn were the main factors concerning negative Zn balance.
